APLICAÇÃO DE DANOS MECÂNICOS E SEUS EFEITOS NA QUALIDADE DE PRODUTOS HORTÍCOLAS, SAFRAS 2019/2020

Problemas sérios na fruticultura brasileira resultam em perdas e desperdício significativo napós-colheita, afetando a qualidade dos frutos e rentabilidade do produtor. Entretanto,problemas causados por danos mecânicos têm efeitos significativo na qualidade dos frutos, jáque eles causam sérios distúrbios fisiológicos e desencadeiam vários processos que atuam nometabolismo, como o aumento da taxa respiratória e transpiração, ocasionando uma maiordesidratação e perda de qualidade. Diante destes problemas, o objetivo deste trabalho é avaliaro efeito de danos mecânicos sobre a qualidade de pós colheita de tangerinas ‘Ponkan’ epêssegos ‘Aurora’ em diferente período de armazenamento na safra de 2020. O experimentofoi conduzido no Laboratório de Pós-colheita do Instituto Federal Catarinense Campus SantaRosa do sul. Os frutos selecionados foram higienizados, selecionados e colocados embandejas de 15 frutos por tratamento. Cada fruto compôs uma repetição, totalizando 15repetições por tratamento para cada data de avaliação. Os tratamentos foram: testemunha,queda, corte e abrasão. As bergamotas ‘Ponkan’ foram armazenadas em frio a 7 oC por 15,30, 45 e 60 dias e para os pêssegos ‘Aurora a 0 oC por 7, 14, 21 e 28 dias. Avaliações foramrealizadas nas saídas de armazenagem para: perda de massa fresca (%), firmeza de polpa (N),sólidos solúveis (ºBRIX) e conteúdo de suco (%). O delineamento experimental foiinteiramente casualizado com esquema fatorial 4x5, referentes aos 4 tratamentos e 5 datas deavaliação, com 15 repetições determinado o fruto como uma unidade experimental. Os dadosforam submetidos à análise de variância (SISVAR) e para a comparação das médias, foiaplicado o teste de Tukey a 5% de probabilidade. A qualidade dos frutos Ponkan é afetadasignificativamente pelos danos mecânicos corte, queda e abrasão, que tendem a afetar asuculência e a acidez dos frutos, diminuindo o tempo de armazenamento dos frutos ediminuição da qualidade. Nos pêssegos ‘Aurora’ o tratamento queda apresentou maioresvalores de perda de massa fresca, mesmo não havendo diferença estatística entre ostratamentos. A firmeza diminuiu ao longo do armazenamento em todos os tratamentos, e otratamento testemunha apresentou maior firmeza. O conteúdo de suco objetivo diminuiu aolongo do armazenamento em todos os tratamentos, porém sem diferença estatística

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

NEOTROPICAL CARNIVORES: a data set on carnivore distribution in the Neotropics

Mammalian carnivores are considered a key group in maintaining ecological health and can indicate potential ecological integrity in landscapes where they occur. Carnivores also hold high conservation value and their habitat requirements can guide management and conservation plans. The order Carnivora has 84 species from 8 families in the Neotropical region: Canidae; Felidae; Mephitidae; Mustelidae; Otariidae; Phocidae; Procyonidae; and Ursidae. Herein, we include published and unpublished data on native terrestrial Neotropical carnivores (Canidae; Felidae; Mephitidae; Mustelidae; Procyonidae; and Ursidae). NEOTROPICAL CARNIVORES is a publicly available data set that includes 99,605 data entries from 35,511 unique georeferenced coordinates. Detection/non-detection and quantitative data were obtained from 1818 to 2018 by researchers, governmental agencies, non-governmental organizations, and private consultants. Data were collected using several methods including camera trapping, museum collections, roadkill, line transect, and opportunistic records. Literature (peer-reviewed and grey literature) from Portuguese, Spanish and English were incorporated in this compilation. Most of the data set consists of detection data entries (n = 79,343; 79.7%) but also includes non-detection data (n = 20,262; 20.3%). Of those, 43.3% also include count data (n = 43,151). The information available in NEOTROPICAL CARNIVORES will contribute to macroecological, ecological, and conservation questions in multiple spatio-temporal perspectives. As carnivores play key roles in trophic interactions, a better understanding of their distribution and habitat requirements are essential to establish conservation management plans and safeguard the future ecological health of Neotropical ecosystems. Our data paper, combined with other large-scale data sets, has great potential to clarify species distribution and related ecological processes within the Neotropics. There are no copyright restrictions and no restriction for using data from this data paper, as long as the data paper is cited as the source of the information used. We also request that users inform us of how they intend to use the data

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis